Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 2,209 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Melanoma Neoplasms Clear all

Conditions: Actinic Keratoses, Aging, Non-Melanoma Skin Cancer
Interventions: Fractionated Laser Resurfacing; Device
Lead sponsor: Wright State University; Other
Eligibility: 60 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Melanoma
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: The Woodlands, Texas

Conditions: Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
Interventions: Bempegaldesleukin, Nivolumab; Biological
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 765 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 62
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more

Conditions: Solid Tumors
Interventions: Epacadostat, Nivolumab, Ipilimumab, Lirilumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 2 more

Conditions: Melanoma
Interventions: 4-peptide and 12-peptide melanoma vaccines; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years to 85 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Uveal Melanoma
Interventions: ADI PEG20, Nivolumab, Ipilimumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma
Interventions: Melaxin (autologous dendritoma vaccine) and BCG; Biological
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Carcinoma (CRC)
Interventions: INCB 99280 with Ipilimumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • San Diego, California + 2 more

Conditions: MelanomaCutaneous Melanoma Resectable, Melanoma
Interventions: RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection; Drug · Procedure
Lead sponsor: Yana Najjar; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sentinel Lymph Node, Melanoma (Skin), Breast Cancer
Interventions: IC-Green KIT; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia • Poughkeepsie, New York • Hershey, Pennsylvania

Conditions: Melanoma
Interventions: Immunotherapeutic GSK2132231A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 15
States / cities: Los Angeles, California • Orange, California • Orlando, Florida + 11 more

Conditions: Malignant Melanoma
Interventions: RO5185426; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
Interventions: XmAb20717; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 17
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 12 more

Conditions: Primary Liver Cancer, SCLC, Lymphoma, Melanoma, Multiple Myeloma, Renal Cell Carcinoma, NSCLC
Interventions: MRX34; Drug
Lead sponsor: Mirna Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 6
States / cities: Scottsdale, Arizona • Dallas, Texas • Houston, Texas + 1 more

Conditions: Melanoma
Interventions: Physical Examination, Solar Simulated Light; Procedure · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 100 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 3
States / cities: Boston, Massachusetts • Cambridge, Massachusetts • Houston, Texas

Conditions: Squamous Cell Cancer, Squamous Cell Carcinoma, Skin Cancer, Non-melanoma Skin Cancer
Interventions: 30% ascorbic acid in DMSO; Drug
Lead sponsor: Center for Biomedical Research, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Melanoma (Skin)
Interventions: hydroxychloroquine; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Malignant Melanoma
Interventions: HyperAcute-Melanoma Vaccine; Biological
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Melanoma
Interventions: "Melanoma Survivor" plaque; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: Not listed
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
Interventions: CMP-001, Nivolumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 16 more

Conditions: Exudative Retinal Detachment and Uveal Melanoma
Interventions: Dexamethasone intravitreal implant; Drug
Lead sponsor: Ivana K. Kim; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma (Skin Cancer)
Interventions: Improve awareness of checking moles, Comparator; Behavioral · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Recurrent Melanoma
Interventions: Indocyanine green solution, Isosulfan blue (ISB), Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC); Drug · Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia

A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Neoadjuvant RP2 + Nivolumab in Patients With Melanoma

SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer

A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Vaccine Treatment for Advanced Malignant Melanoma

Skin Care Behaviors Among Melanoma Survivors and Their Families

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Dexamethasone Implant for Retinal Detachment in Uveal Melanoma

Promoting Early Detection of Melanoma During the Mammography Experience

Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma